VBI Vaccines, Inc. – (NASDAQ:VBIV) was the target of a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 423,005 shares, a decline of 50.3% from the January 12th total of 850,420 shares. Based on an average daily trading volume, of 96,036 shares, the days-to-cover ratio is currently 4.4 days. Approximately 1.1% of the shares of the company are short sold.
Shares of VBI Vaccines (NASDAQ VBIV) opened at $3.85 on Monday. VBI Vaccines has a 52 week low of $3.04 and a 52 week high of $6.60. The company has a current ratio of 1.03, a quick ratio of 0.97 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $245.65, a P/E ratio of -5.27 and a beta of 1.62.
VBI Vaccines (NASDAQ:VBIV) last posted its quarterly earnings data on Monday, November 13th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.01). VBI Vaccines had a negative return on equity of 49.17% and a negative net margin of 4,463.06%. The firm had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.15 million. equities analysts anticipate that VBI Vaccines will post -0.9 earnings per share for the current year.
A number of large investors have recently bought and sold shares of the business. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in VBI Vaccines during the 4th quarter worth approximately $7,000,000. BlackRock Inc. grew its position in shares of VBI Vaccines by 63.7% in the fourth quarter. BlackRock Inc. now owns 1,509,286 shares of the biopharmaceutical company’s stock valued at $6,445,000 after purchasing an additional 587,036 shares in the last quarter. Cambridge Investment Research Advisors Inc. grew its position in shares of VBI Vaccines by 2.7% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 1,415,650 shares of the biopharmaceutical company’s stock valued at $5,450,000 after purchasing an additional 37,660 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of VBI Vaccines in the third quarter valued at approximately $1,329,000. Finally, Northern Trust Corp purchased a new stake in shares of VBI Vaccines in the second quarter valued at approximately $883,000. Institutional investors own 20.89% of the company’s stock.
A number of equities analysts recently weighed in on VBIV shares. Canaccord Genuity started coverage on VBI Vaccines in a report on Wednesday, November 1st. They issued a “buy” rating and a $10.00 price target for the company. Zacks Investment Research raised VBI Vaccines from a “sell” rating to a “hold” rating in a report on Wednesday, October 18th. BidaskClub cut VBI Vaccines from a “hold” rating to a “sell” rating in a report on Thursday, December 14th. Finally, BMO Capital Markets started coverage on VBI Vaccines in a report on Wednesday, November 15th. They issued an “outperform” rating and a $11.00 price target for the company. Two research analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $8.75.
About VBI Vaccines
VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.